Check out the latest advancement in our partnership with A*STAR - Agency for Science, Technology and Research to spur innovation in human health in Singapore, and how Apriori Bio is working to develop stronger protections against influenza.
We’re thrilled to announce our new strategic partnership with A*STAR Infectious Diseases Labs - A*STAR IDL to co-develop next generation self-amplifying RNA (saRNA) vaccines against seasonal and pandemic influenza. This collaboration unites our Octavia™ platform, which uses AI to intelligently design prospective, variant-resilient antigens, with A*STAR IDL’s cutting-edge saRNA delivery technologies. Together, we aim to pioneer vaccines that provide broader and longer-lasting protection against influenza. To kick off the partnership, Apriori leaders Craig Williams, Harry Kleanthous, and Raffaella Squilloni, had the privilege of visiting A*STAR’s offices in Singapore. It was an inspiring start to what we believe will be transformative work for global health. The collaboration takes place under the ongoing Flagship Pioneering institutional partnership with A*STAR. Read the full press release here: https://lnkd.in/ehsD5C49
